Epiconcept, Paris, France.
European Centre for Disease Prevention and Control, Stockholm, Sweden.
Euro Surveill. 2023 Nov;28(47). doi: 10.2807/1560-7917.ES.2023.28.47.2300187.
IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period).MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received < 150 and ≥ 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition.ResultsWe included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively.ConclusionsOur results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose.
引言
自 2021 年初以来，I-MOVE-COVID-19 和 VEBIS 医院网络一直在参与的欧洲国家测量 COVID-19 疫苗的有效性（VE）。
目的
我们旨在测量 2021 年 12 月至 2022 年 7 月（Omicron 主导期）期间≥20 岁因严重急性呼吸道感染（SARI）住院的患者中 PCR 确诊的 SARS-CoV-2 的 VE。
方法
在两个网络中，46 家医院（13 个国家）遵循类似的测试阴性病例对照方案。我们将完整的初级系列疫苗接种（PSV）和第一加强剂量疫苗接种定义为最后一剂疫苗的接种时间在症状出现前≥14 天（将第一加强剂分为距最后一剂 PSV 剂量接受后<150 和≥150 天）。我们通过在固定效应中调整站点，以及通过拭子日期、年龄、性别和是否存在/不存在至少一种常见的慢性疾病，对总体、疫苗类别/产品、年龄组和第一 mRNA 加强剂量后时间进行 VE 测量。
结果
我们纳入了 2779 例病例和 2362 例对照。所有疫苗产品联合预防实验室确诊的 SARS-CoV-2 住院治疗的 VE 对于完整的 PSV（最后一剂疫苗接种时间在发病前≥150 天）为 43%（95%CI：29-54），而添加一剂加强针后为 59%（95%CI：51-66）。加强针接种后 14-59 天、60-119 天和 120-179 天发病的 VE 分别为 85%（95%CI：78-89）、70%（95%CI：61-77）和 36%（95%CI：17-51）。
结论
我们的结果表明，在 Omicron 期间，随着第一剂 mRNA 加强针的接种，SARI 住院治疗的观察 VE 有所提高，特别是对于那些在第一剂加强针接种后 120 天内出现症状的患者。
